GlassScriptPhysician profile
Karen C Lash
NPI 1720392848
$1,996.21
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $738 · 2022: $963 · 2023: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $295.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $247.11 | 2021-2022 | |
| Seagen INC. | $135.17 | 2021-2023 | Padcev |
| Pfizer INC. | $127.93 | 2021-2022 | |
| Amgen INC. | $126.36 | 2021-2023 | Kyprolis |
| Novartis Pharmaceuticals Corporation | $124.17 | 2022 | |
| Incyte Corporation | $122.88 | 2021-2023 | Jakafi |
| Gilead Sciences, INC. | $90.26 | 2021-2023 | Trodelvy |
| Jazz Pharmaceuticals INC. | $80.99 | 2021-2023 | |
| Celgene Corporation | $78.85 | 2021-2022 | |
| Genzyme Corporation | $70.46 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $63.81 | 2021-2023 | Imfinzi |
| Merck Sharp & Dohme LLC | $61.46 | 2021-2022 | |
| Daiichi Sankyo INC. | $60.87 | 2021-2022 | |
| Beigene USA, INC. | $60.69 | 2021-2022 | |
| Janssen Biotech, INC. | $54.40 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $49.77 | 2021-2023 | Imbruvica |
| Takeda Pharmaceuticals U.S.A., INC. | $48.02 | 2021-2022 | |
| Astellas Pharma US INC | $46.84 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $38.62 | 2023 | Libtayo |
| Dova Pharmaceuticals | $34.55 | 2021 | |
| Array Biopharma INC | $32.11 | 2021-2022 | |
| Puma Biotechnology, INC. | $27.37 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.20 | 2021 | |
| Myriad Genetic Laboratories, INC. | $25.04 | 2023 | Myrisk |
| Genentech USA, INC. | $24.42 | 2023 | Venclexta |
| Eisai INC. | $24.22 | 2022 | |
| Sobi, INC | $22.32 | 2022 | |
| Eusa Pharma (US) LLC | $22.32 | 2021 | |
| Tersera Therapeutics LLC | $18.68 | 2022 | |
| Aveo Pharmaceuticals, INC. | $18.00 | 2022 | |
| Blueprint Medicines Corporation | $17.96 | 2021 | |
| Kyowa Kirin, INC. | $14.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Lash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.